


CLAIMS

1. A compound of general formula (I):



(I)

5

in which

R¹ represents methyl,

R² represents C₃-C₄-alkyl substituted with two substituents which are the same or different and independently selected from the group consisting of OH and -COOH, or 5-membered heterocycloalkyl having one O atom and substituted at any carbon atom with one or two substituents which are the same or different, and independently selected from the group consisting of

oxo and OH,
or stereoisomers, hydrates, solvates, salts thereof, or mixtures of same, as described and defined herein.

15

2. The compound according to claim 1, wherein R¹ represents methyl.

3. The compound according to claim 1 or 2, wherein

R² represents C₃-alkyl optionally substituted with OH and COOH.

20

4. The compound according to any one of claims 1 to 3, wherein

R² represents C₄-alkyl optionally substituted with two OH.

5. The compound according to any one of claims 1 to 4, wherein

R² represents C(CH₂OH)(CH₂)₂OH.

25

6. The compound according to any one of claims 1 to 5, wherein
 R^2 represents tetrahydrofuranyl substituted at any carbon atom with OH.
- 5 7. The compound according to any one of claims 1 to 6, wherein
 R^1 represents methyl, and
 R^2 represents $C(CH_2OH)(CH_2)_2OH$.
8. The compound according to any one of claims 1 to 7, wherein which is selected
10 from the group consisting of:
3-[[{(2R)-1,4-dihydroxybutan-2-yl]oxy}-5-(5-methyl-1,3-thiazol-2-yl)-N-{{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide,
rel-3-[[{(3R,5R)-5-Hydroxytetrahydrofuran-3-yl]oxy}-5-(5-methyl-1,3-thiazol-2-yl)-
N-{{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide,
15 [[{(3R,5R)-5-Hydroxytetrahydrofuran-3-yl]oxy}-5-(5-methyl-1,3-thiazol-2-yl)-N-
{{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide,
[[{(3R,5S)-5-hydroxytetrahydrofuran-3-yl]oxy}-5-(5-methyl-1,3-thiazol-2-yl)-N-
{{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide,
(3R)-4-hydroxy-3-[3-(5-methyl-1,3-thiazol-2-yl)-5-{{(1R)-1-[2-
20 (trifluoromethyl)pyrimidin-5-yl]ethyl}carbamoyl]phenoxy]butanoic acid,
2-{3-[(3R)-tetrahydrofuran-3-yloxy]-5-{{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-
yl]ethyl}carbamoyl}phenyl}-1,3-thiazole-5-carboxylic acid,
or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same.
- 25 9. A compound of general formula (I) according to any one of claims 1 to 8, or an
enantiomer, diastereomer, racemate, hydrate, solvate, or a pharmaceutically
acceptable salt thereof, or a mixture thereof, for use in the treatment of a disease.
10. The compound for use according to claim 9, wherein the disease is a neurogenic
30 disorder, such as genitourinary, gastrointestinal, respiratory, cardiovascular

disease associated with autonomic imbalance caused by increased chemoreceptor sensitivity, and pain-related diseases.

11. Use of a compound of general formula (I) according to any one of claims 1 to 8,
5 or an enantiomer, diastereomer, racemate, hydrate, solvate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, for the preparation of a medicament for the prophylaxis or treatment of a disease.
12. The compound for use according to claim 10, wherein the genitourinary disease
10 is selected from the group consisting of dysmenorrhea, dyspareunia, endometriosis, adenomyosis, endometriosis-associated pain, endometriosis-associated proliferation, pelvic hypersensitivity, dysuria, dyschezia.
13. The compound for use according to claim 10, wherein the genitourinary disease
15 is selected from the group consisting of bladder outlet obstruction, urinary incontinence conditions, reduced bladder capacity, increased frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy, prostatic hyperplasia, prostatitis, detrusor hyperreflexia, pelvic hypersensitivity, urethritis, prostatitis, prostatodynia, cystitis,
20 Interstitial cystitis, idiopathic bladder hypersensitivity, overactive bladder, and symptoms related to overactive bladder wherein said symptoms are increased urinary frequency, nocturia, urinary urgency or urge incontinence.
14. The compound for use according to claim 10, wherein the respiratory disease is
25 selected from the group consisting of chronic obstructive pulmonary disorder (COPD), asthma, bronchospasm, pulmonary fibrosis, acute cough, and chronic cough including chronic idiopathic and chronic refractory cough.
15. A pharmaceutical composition comprising a compound of general formula (I)
30 according to any one of claims 1 to 8, or an enantiomer, diastereomer, racemate, hydrate, solvate, a pharmaceutically acceptable salt thereof, or a mixture thereof, and one or more pharmaceutically acceptable excipients.

16. A pharmaceutical combination according to claim 15, wherein further active ingredients are selected from the group consisting of cough suppressants, NSAIDS (Non-Steroidal Antiinflammatory Drug), Combined Oral Contraceptives (COC), GnRAH antagonists, Selective Progesterone Receptor Modulators (SPRMs), Progesterone antagonists, P2X3 inhibitors, NK1 inhibitors and nicotinic Acetylcholine modulators.